Free Trial

GeneDx (WGSWW) Financials

$0.17 +0.03 (+22.23%)
As of 04/17/2025 02:30 PM Eastern
Annual Income Statements for GeneDx

Annual Income Statements for GeneDx

This table shows GeneDx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-33 -241 -245 -549 -176 -52
Consolidated Net Income / (Loss)
-30 -241 -245 -549 -176 -52
Net Income / (Loss) Continuing Operations
-30 -241 -245 -549 -176 -52
Total Pre-Tax Income
-30 -241 -245 -598 -177 -53
Total Operating Income
-30 -242 -446 -668 -181 -23
Total Gross Profit
83 4.03 -17 -27 90 194
Total Revenue
196 179 212 235 203 305
Operating Revenue
196 179 212 235 203 305
Total Cost of Revenue
113 175 229 261 113 111
Operating Cost of Revenue
113 175 229 261 113 111
Total Operating Expenses
113 246 430 641 271 218
Selling, General & Admin Expense
29 101 206 216 134 101
Marketing Expense
39 63 113 122 61 67
Research & Development Expense
35 73 105 86 58 46
Other Operating Expenses / (Income)
9.45 9.40 5.66 6.31 7.22 3.41
Impairment Charge
- 0.00 0.00 210 10 0.00
Total Other Income / (Expense), net
0.71 0.65 201 70 2.73 -29
Interest & Investment Income
0.99 0.51 0.08 - 1.11 -3.03
Other Income / (Expense), net
0.50 2.62 204 70 1.62 -26
Income Tax Expense
0.00 0.00 0.00 -49 -0.93 -0.34
Basic Earnings per Share
($264,056.00) ($47,036.00) ($2.27) ($53.63) ($7.23) ($1.94)
Weighted Average Basic Shares Outstanding
124.00 5.13K 108.08M 10.24M 24.31M 26.89M
Diluted Earnings per Share
($264,056.00) ($47,036.00) ($2.27) ($53.63) ($7.23) ($1.94)
Weighted Average Diluted Shares Outstanding
124.00 5.13K 108.08M 10.24M 24.31M 26.89M
Weighted Average Basic & Diluted Shares Outstanding
- - 244.96M 798.25M 26.05M 28.07M

Quarterly Income Statements for GeneDx

This table shows GeneDx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-78 -309 -61 -47 -42 -26 -20 -29 -8.31 5.44
Consolidated Net Income / (Loss)
-78 -309 -61 -47 -42 -26 -20 -29 -8.31 5.44
Net Income / (Loss) Continuing Operations
-78 -309 -61 -47 -42 -26 -20 -29 -8.31 5.44
Total Pre-Tax Income
-78 -309 -61 -47 -42 -26 -20 -29 -8.36 5.41
Total Operating Income
-91 -325 -60 -52 -43 -26 -14 -11 -7.78 8.81
Total Gross Profit
14 -16 15 19 25 31 37 43 48 66
Total Revenue
83 61 43 49 53 57 62 71 77 96
Operating Revenue
83 61 43 49 53 57 62 71 77 96
Total Cost of Revenue
70 78 28 30 28 27 25 28 29 29
Operating Cost of Revenue
70 78 28 30 28 27 25 28 29 29
Total Operating Expenses
104 309 76 70 68 56 51 54 56 57
Selling, General & Admin Expense
55 43 44 37 26 27 22 25 26 27
Marketing Expense
34 29 13 15 17 16 16 17 17 18
Research & Development Expense
13 24 15 17 14 12 12 11 12 12
Other Operating Expenses / (Income)
1.70 1.60 1.75 0.72 2.79 1.96 0.97 0.87 0.77 0.79
Total Other Income / (Expense), net
13 16 -0.77 4.71 0.51 -1.71 -6.66 -19 -0.58 -3.39
Other Income / (Expense), net
13 16 -0.74 3.63 -0.54 -0.73 -6.06 -18 0.26 -2.69
Income Tax Expense
-0.07 0.09 -0.15 -0.20 -0.17 -0.41 -0.08 -0.19 -0.05 -0.02
Basic Earnings per Share
($6.72) ($30.16) ($3.04) ($1.84) ($1.64) ($1.06) ($0.78) ($1.10) ($0.31) $0.20
Weighted Average Basic Shares Outstanding
11.54M 10.24M 20.06M 25.42M 25.79M 24.31M 26.06M 26.62M 27.10M 26.89M
Diluted Earnings per Share
($6.72) ($30.16) ($3.04) ($1.84) ($1.64) ($1.06) ($0.78) ($1.10) ($0.31) $0.20
Weighted Average Diluted Shares Outstanding
11.54M 10.24M 20.06M 25.42M 25.79M 24.31M 26.06M 26.62M 27.10M 26.89M
Basic & Diluted Earnings per Share
- ($30.16) - - - ($1.06) - - - $0.20
Weighted Average Basic & Diluted Shares Outstanding
386.80M 798.25M 25.59M 25.77M 25.88M 26.05M 26.14M 26.94M 27.47M 28.07M

Annual Cash Flow Statements for GeneDx

This table details how cash moves in and out of GeneDx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
114 3.95 283 -263 -38 -14
Net Cash From Operating Activities
-19 -93 -190 -319 -180 -28
Net Cash From Continuing Operating Activities
-19 -93 -192 -319 -180 -29
Net Income / (Loss) Continuing Operations
-30 -241 -245 -549 -176 -52
Consolidated Net Income / (Loss)
-30 -241 -245 -549 -176 -52
Depreciation Expense
6.41 12 22 59 34 22
Non-Cash Adjustments To Reconcile Net Income
6.73 123 25 183 -1.35 23
Changes in Operating Assets and Liabilities, net
-2.16 14 6.65 -13 -37 -21
Net Cash From Investing Activities
-15 -32 -21 -141 -44 -30
Net Cash From Continuing Investing Activities
-15 -32 -21 -141 -44 -30
Purchase of Property, Plant & Equipment
-15 -32 -21 -14 -5.71 -5.49
Acquisitions
- 0.00 0.00 -127 -12 0.00
Purchase of Investments
- - - 0.00 -48 -66
Sale of Property, Plant & Equipment
- - - 0.00 4.03 0.00
Sale and/or Maturity of Investments
- - - 0.00 18 42
Net Cash From Financing Activities
148 129 494 197 186 44
Net Cash From Continuing Financing Activities
148 129 498 197 186 44
Repayment of Debt
-1.71 -0.19 -10 0.00 -2.00 -0.50
Issuance of Debt
0.00 16 0.00 0.00 49 0.00
Issuance of Common Equity
0.00 0.00 793 198 143 47
Other Financing Activities, net
31 -4.01 -2.46 -0.34 -3.31 -2.33
Cash Interest Paid
0.31 1.75 2.75 1.93 3.04 6.68
Cash Income Taxes Paid
0.00 0.00 0.35 1.24 1.47 1.17

Quarterly Cash Flow Statements for GeneDx

This table details how cash moves in and out of GeneDx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-93 -67 77 -57 -69 12 -16 -28 1.82 27
Net Cash From Operating Activities
-88 -65 -56 -54 -41 -30 -16 -4.51 -4.40 -3.18
Net Cash From Continuing Operating Activities
-88 -65 -56 -54 -41 -30 -16 -4.51 -4.40 -3.45
Net Income / (Loss) Continuing Operations
-78 -309 -61 -47 -42 -26 -20 -29 -8.31 5.44
Consolidated Net Income / (Loss)
-78 -309 -61 -47 -42 -26 -20 -29 -8.31 5.44
Depreciation Expense
11 34 8.64 10 8.67 6.09 5.25 5.22 5.93 5.56
Non-Cash Adjustments To Reconcile Net Income
-8.74 194 1.80 -7.01 6.60 -2.74 5.50 22 2.89 -7.99
Changes in Operating Assets and Liabilities, net
-13 16 -5.01 -10 -14 -7.44 -6.92 -2.85 -4.90 -6.45
Net Cash From Investing Activities
-4.28 -2.84 -0.46 -11 -27 -4.86 0.84 -23 -7.76 -0.52
Net Cash From Continuing Investing Activities
-4.28 -2.84 -0.46 -11 -27 -4.86 0.84 -23 -7.76 -0.52
Purchase of Property, Plant & Equipment
-4.28 -2.84 -0.46 -2.76 -0.11 -2.38 -0.44 -1.35 -0.65 -3.05
Purchase of Investments
- - 0.00 - -44 -3.74 -5.17 -24 -23 -14
Sale and/or Maturity of Investments
- - 0.00 - 17 1.10 6.45 2.87 16 16
Net Cash From Financing Activities
-0.65 0.07 133 7.39 -0.91 47 -0.44 -0.39 14 31
Net Cash From Continuing Financing Activities
-0.65 0.07 133 7.39 -0.91 47 -0.44 -0.39 14 31
Repayment of Debt
- - -2.00 - - - 0.00 - -0.20 -0.30
Issuance of Common Equity
-0.05 - 135 7.56 - - 0.00 - 15 32
Other Financing Activities, net
-0.59 0.07 -0.78 -0.18 -0.91 -1.45 -0.44 -0.39 -0.42 -1.08
Cash Interest Paid
0.60 0.14 0.58 0.36 0.17 1.93 2.02 2.01 2.04 0.61
Cash Income Taxes Paid
0.12 0.75 0.10 0.90 0.18 0.29 0.30 0.26 0.35 0.26

Annual Balance Sheets for GeneDx

This table presents GeneDx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Total Assets
252 554 491 419 419
Total Current Assets
174 484 213 182 198
Cash & Equivalents
108 401 124 100 85
Short-Term Investments
- - 0.00 30 56
Accounts Receivable
32 27 43 33 38
Inventories, net
25 33 14 8.78 11
Prepaid Expenses
4.56 19 32 11 8.50
Plant, Property, & Equipment, net
63 63 52 32 33
Total Noncurrent Assets
14 7.83 227 204 189
Intangible Assets
- 0.00 187 173 159
Other Noncurrent Operating Assets
14 7.83 40 31 30
Total Liabilities & Shareholders' Equity
252 554 491 419 419
Total Liabilities
247 166 237 191 174
Total Current Liabilities
73 101 144 59 55
Accounts Payable
28 47 85 37 30
Other Current Liabilities
30 34 59 21 25
Total Noncurrent Liabilities
174 65 93 132 119
Long-Term Debt
19 11 6.25 53 52
Capital Lease Obligations
21 0.00 60 63 61
Noncurrent Deferred & Payable Income Tax Liabilities
- 0.00 2.66 1.56 0.97
Other Noncurrent Operating Liabilities
2.07 54 24 15 5.52
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-330 388 254 228 245
Total Preferred & Common Equity
-330 388 254 228 245
Preferred Stock
0.00 0.00 0.00 0.00 0.00
Total Common Equity
-330 388 254 228 245
Common Stock
0.00 964 1,378 1,528 1,597
Retained Earnings
-330 -575 -1,124 -1,300 -1,352
Accumulated Other Comprehensive Income / (Loss)
- - 0.00 0.43 0.83

Quarterly Balance Sheets for GeneDx

This table presents GeneDx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
829 545 476 417 395 389 409
Total Current Assets
307 272 213 172 163 162 186
Cash & Equivalents
191 202 157 87 84 56 58
Short-Term Investments
- - - 27 29 51 59
Accounts Receivable
44 34 34 32 29 26 38
Inventories, net
44 12 12 9.35 12 10 11
Prepaid Expenses
18 12 11 16 9.97 19 20
Plant, Property, & Equipment, net
84 50 43 36 31 31 31
Total Noncurrent Assets
438 223 220 210 200 196 191
Intangible Assets
190 183 180 176 169 166 162
Other Noncurrent Operating Assets
66 40 40 34 31 30 29
Total Liabilities & Shareholders' Equity
829 545 476 417 395 389 409
Total Liabilities
268 217 180 163 187 195 204
Total Current Liabilities
162 119 84 68 51 68 77
Accounts Payable
89 74 55 39 32 52 56
Other Current Liabilities
74 45 30 29 18 16 21
Total Noncurrent Liabilities
105 98 96 95 137 127 127
Long-Term Debt
11 6.25 6.25 6.05 52 52 52
Capital Lease Obligations
62 64 64 64 62 61 60
Noncurrent Deferred & Payable Income Tax Liabilities
2.60 2.51 2.25 2.06 1.42 1.17 1.05
Other Noncurrent Operating Liabilities
30 25 24 23 21 13 14
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
561 328 296 254 207 194 205
Total Preferred & Common Equity
561 328 296 254 207 194 205
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
561 328 296 254 207 194 205
Common Stock
1,377 1,514 1,528 1,529 1,527 1,543 1,561
Retained Earnings
-816 -1,185 -1,232 -1,274 -1,320 -1,350 -1,358
Accumulated Other Comprehensive Income / (Loss)
- - - - 0.29 0.46 0.92

Annual Metrics and Ratios for GeneDx

This table displays calculated financial ratios and metrics derived from GeneDx's official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - -
Revenue Growth
0.00% -8.59% 18.33% 10.60% -13.69% 50.79%
EBITDA Growth
0.00% -868.59% 3.02% -143.73% 73.01% 80.97%
EBIT Growth
0.00% -700.33% -1.36% -146.20% 70.04% 72.29%
NOPAT Growth
0.00% -695.69% -84.36% -49.65% 72.95% 87.15%
Net Income Growth
0.00% -712.48% -1.68% -123.72% 67.98% 70.25%
EPS Growth
0.00% 82.19% 100.00% -123.72% 86.52% 73.17%
Operating Cash Flow Growth
0.00% -397.27% -104.49% -67.59% 43.56% 84.18%
Free Cash Flow Firm Growth
0.00% 0.00% -240.96% -79.05% 78.36% 86.34%
Invested Capital Growth
0.00% 0.00% 97.58% 13,472.10% 8.91% 1.59%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 1.54% -1.90% 14.30%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% -81.56% 63.68% 52.69%
EBIT Q/Q Growth
0.00% 0.00% 0.00% -82.20% 61.23% 38.70%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% -45.60% 62.36% 59.74%
Net Income Q/Q Growth
0.00% 0.00% 0.00% -95.78% 61.69% 37.38%
EPS Q/Q Growth
0.00% 0.00% 0.00% -95.78% 59.36% 37.01%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -21.46% -4.13% 16.19% 48.35%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% -39.87% 36.43%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% -55.74% 1.71% 8.21%
Profitability Metrics
- - - - - -
Gross Margin
42.20% 2.25% -7.82% -11.40% 44.43% 63.64%
EBITDA Margin
-11.98% -126.94% -104.04% -229.26% -71.70% -9.05%
Operating Margin
-15.50% -134.95% -210.25% -284.48% -89.15% -7.60%
EBIT Margin
-15.25% -133.49% -114.34% -254.53% -88.35% -16.24%
Profit (Net Income) Margin
-15.14% -134.58% -115.64% -233.91% -86.77% -17.12%
Tax Burden Percent
100.00% 100.00% 100.00% 91.80% 99.48% 99.35%
Interest Burden Percent
99.31% 100.82% 101.14% 100.11% 98.72% 106.11%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% -480.40% -61.74% -7.55%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% -443.90% 74.98% 160.55%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 309.33% -11.24% -14.55%
Return on Equity (ROE)
0.00% -5,500.00% -125.04% -171.07% -72.97% -22.10%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% -339.15% -70.26% -9.13%
Operating Return on Assets (OROA)
0.00% -95.12% -60.23% -114.32% -39.35% -11.84%
Return on Assets (ROA)
0.00% -95.91% -60.91% -105.06% -38.64% -12.48%
Return on Common Equity (ROCE)
0.00% 413,692.00% -18.49% -171.07% -72.97% -22.10%
Return on Equity Simple (ROE_SIMPLE)
0.00% 73.12% -63.23% -216.39% -77.09% -21.32%
Net Operating Profit after Tax (NOPAT)
-21 -169 -312 -467 -126 -16
NOPAT Margin
-10.85% -94.46% -147.18% -199.13% -62.41% -5.32%
Net Nonoperating Expense Percent (NNEP)
0.00% -221.79% 29.45% -36.50% -136.72% -168.10%
Return On Investment Capital (ROIC_SIMPLE)
- - - - -36.79% -4.54%
Cost of Revenue to Revenue
57.80% 97.75% 107.82% 111.40% 55.57% 36.36%
SG&A Expenses to Revenue
15.03% 56.18% 97.07% 92.11% 66.03% 33.10%
R&D to Revenue
17.80% 40.54% 49.56% 36.73% 28.76% 14.97%
Operating Expenses to Revenue
57.70% 137.19% 202.43% 273.08% 133.59% 71.24%
Earnings before Interest and Taxes (EBIT)
-30 -239 -243 -597 -179 -50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-24 -228 -221 -538 -145 -28
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 0.00 2.77 0.40 0.31 8.61
Price to Tangible Book Value (P/TBV)
0.00 0.00 2.77 1.52 1.29 24.37
Price to Revenue (P/Rev)
1.96 3.41 5.07 0.43 0.35 6.91
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.23 0.27 9.60
Enterprise Value to Revenue (EV/Rev)
0.00 4.91 3.24 0.19 0.28 6.82
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
0.00 9.86 0.03 0.26 0.51 0.46
Long-Term Debt to Equity
0.00 9.06 0.03 0.26 0.51 0.46
Financial Leverage
0.00 -14.79 -1.16 -0.70 -0.15 -0.09
Leverage Ratio
0.00 57.35 2.05 1.63 1.89 1.77
Compound Leverage Factor
0.00 57.82 2.08 1.63 1.86 1.88
Debt to Total Capital
0.00% 90.79% 2.76% 20.71% 33.65% 31.51%
Short-Term Debt to Total Capital
0.00% 7.36% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 83.43% 2.76% 20.71% 33.65% 31.51%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 701.97% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% -692.76% 97.24% 79.29% 66.35% 68.49%
Debt to EBITDA
0.00 -0.19 -0.05 -0.12 -0.80 -4.08
Net Debt to EBITDA
0.00 0.29 1.76 0.11 0.10 1.03
Long-Term Debt to EBITDA
0.00 -0.17 -0.05 -0.12 -0.80 -4.08
Debt to NOPAT
0.00 -0.26 -0.04 -0.14 -0.91 -6.94
Net Debt to NOPAT
0.00 0.38 1.25 0.12 0.11 1.74
Long-Term Debt to NOPAT
0.00 -0.23 -0.04 -0.14 -0.91 -6.94
Altman Z-Score
0.00 -2.30 2.20 -6.32 -4.70 3.51
Noncontrolling Interest Sharing Ratio
0.00% 7,621.67% 85.21% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - -
Current Ratio
0.00 2.37 4.77 1.47 3.10 3.61
Quick Ratio
0.00 1.91 4.22 1.16 2.77 3.26
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -109 -371 -665 -144 -20
Operating Cash Flow to CapEx
-121.17% -291.26% -916.16% -2,228.42% -10,742.22% -518.96%
Free Cash Flow to Firm to Interest Expense
0.00 -44.02 -130.98 -998.28 0.00 0.00
Operating Cash Flow to Interest Expense
-23.92 -37.64 -67.17 -479.21 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-43.66 -50.57 -74.50 -500.72 0.00 0.00
Efficiency Ratios
- - - - - -
Asset Turnover
0.00 0.71 0.53 0.45 0.45 0.73
Accounts Receivable Turnover
0.00 5.55 7.21 6.71 5.32 8.67
Inventory Turnover
0.00 7.02 7.83 11.10 10.03 11.43
Fixed Asset Turnover
0.00 2.84 3.37 4.11 4.82 9.35
Accounts Payable Turnover
0.00 6.22 6.06 3.96 1.84 3.29
Days Sales Outstanding (DSO)
0.00 65.81 50.65 54.36 68.61 42.09
Days Inventory Outstanding (DIO)
0.00 51.98 46.60 32.89 36.39 31.93
Days Payable Outstanding (DPO)
0.00 58.64 60.21 92.28 198.35 110.93
Cash Conversion Cycle (CCC)
0.00 59.15 37.05 -5.03 -93.35 -36.91
Capital & Investment Metrics
- - - - - -
Invested Capital
0.00 -60 -1.47 196 213 217
Invested Capital Turnover
0.00 -5.93 -6.85 2.41 0.99 1.42
Increase / (Decrease) in Invested Capital
0.00 -60 59 198 17 3.40
Enterprise Value (EV)
0.00 881 686 44 57 2,083
Market Capitalization
385 611 1,076 102 71 2,111
Book Value per Share
$0.00 ($5.96) $1.61 $0.66 $8.81 $8.93
Tangible Book Value per Share
$0.00 ($5.96) $1.61 $0.17 $2.14 $3.15
Total Capital
0.00 48 399 320 344 358
Total Debt
0.00 43 11 66 116 113
Total Long-Term Debt
0.00 40 11 66 116 113
Net Debt
0.00 -65 -390 -58 -15 -28
Capital Expenditures (CapEx)
15 32 21 14 1.68 5.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -3.96 -18 -56 -6.63 1.97
Debt-free Net Working Capital (DFNWC)
0.00 104 382 68 124 143
Net Working Capital (NWC)
0.00 101 382 68 124 143
Net Nonoperating Expense (NNE)
8.41 72 -67 82 49 36
Net Nonoperating Obligations (NNO)
0.00 -65 -390 -58 -15 -28
Total Depreciation and Amortization (D&A)
6.41 12 22 59 34 22
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -2.21% -8.63% -23.69% -3.27% 0.64%
Debt-free Net Working Capital to Revenue
0.00% 58.09% 180.15% 29.11% 60.98% 46.87%
Net Working Capital to Revenue
0.00% 56.14% 180.15% 29.11% 60.98% 46.87%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 ($53.79) ($7.23) ($1.94)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 0.00 10.24M 24.31M 26.89M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 ($53.79) ($7.23) ($1.94)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 0.00 10.24M 24.31M 26.89M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 0.00 24.19M 26.05M 28.07M
Normalized Net Operating Profit after Tax (NOPAT)
-21 -169 -312 -320 -119 -16
Normalized NOPAT Margin
-10.85% -94.46% -147.18% -136.46% -58.81% -5.32%
Pre Tax Income Margin
-15.14% -134.58% -115.64% -254.81% -87.23% -17.23%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
-38.20 -96.76 -85.59 -896.95 0.00 0.00
NOPAT to Interest Expense
-27.19 -68.47 -110.16 -701.74 0.00 0.00
EBIT Less CapEx to Interest Expense
-57.94 -109.68 -92.92 -918.45 0.00 0.00
NOPAT Less CapEx to Interest Expense
-46.93 -81.39 -117.49 -723.24 0.00 0.00
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% -21.09% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -21.09% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for GeneDx

This table displays calculated financial ratios and metrics derived from GeneDx's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
92.77% 6.14% -20.03% 34.66% -35.96% -6.41% 44.70% 44.77% 44.22% 66.57%
EBITDA Growth
-272.86% -717.40% 25.25% 69.95% 48.16% 92.62% 72.41% 38.26% 95.44% 157.54%
EBIT Growth
-333.13% -682.29% 19.73% 64.30% 44.10% 91.46% 67.72% 40.68% 82.73% 123.17%
NOPAT Growth
27.98% -180.60% 32.41% 68.26% 52.69% 92.11% 77.37% 79.51% 81.89% 149.28%
Net Income Growth
-337.03% -668.35% 20.69% 45.51% 45.49% 91.65% 66.82% 37.56% 80.34% 121.10%
EPS Growth
-337.03% -668.35% 20.69% 78.04% 75.60% 96.49% 74.34% 40.22% 81.10% 118.87%
Operating Cash Flow Growth
-24.56% -24.37% 31.82% 36.79% 53.34% 53.82% 70.46% 91.58% 89.34% 89.34%
Free Cash Flow Firm Growth
-241.98% 0.00% -193.63% 179.42% 135.89% 91.67% 76.63% -98.95% -98.02% 115.38%
Invested Capital Growth
850.55% 13,472.10% 122.58% -50.88% -52.61% 8.91% 13.04% -4.45% -4.51% 1.59%
Revenue Q/Q Growth
130.13% -26.29% -29.68% 12.90% 9.44% 7.72% 8.72% 12.96% 9.02% 24.41%
EBITDA Q/Q Growth
46.37% -309.15% 80.92% 28.22% 7.48% 41.78% 24.26% -60.62% 93.17% 835.35%
EBIT Q/Q Growth
42.09% -296.99% 80.23% 21.46% 9.33% 39.38% 21.75% -44.34% 73.60% 181.32%
NOPAT Q/Q Growth
44.16% -257.74% 81.42% 14.48% 16.77% 40.32% 46.73% 22.55% 26.46% 262.41%
Net Income Q/Q Growth
9.52% -297.99% 80.25% 23.40% 9.49% 39.05% 21.47% -44.14% 71.51% 165.42%
EPS Q/Q Growth
9.52% -297.99% 80.25% 39.47% 10.87% 35.37% 26.42% -41.03% 71.82% 164.52%
Operating Cash Flow Q/Q Growth
-4.39% 26.83% 14.07% 3.71% 22.94% 27.58% 45.03% 72.55% 2.44% 27.58%
Free Cash Flow Firm Q/Q Growth
-148.36% 24.86% 66.14% 225.67% 12.22% -117.45% 5.04% 105.67% 110.31% 35.74%
Invested Capital Q/Q Growth
3.87% -55.74% -5.85% 13.49% 0.21% 1.71% -2.28% -4.07% 0.15% 8.21%
Profitability Metrics
- - - - - - - - - -
Gross Margin
16.28% -26.61% 35.32% 38.51% 47.39% 53.56% 59.93% 60.91% 62.22% 69.22%
EBITDA Margin
-80.74% -448.19% -121.62% -77.31% -65.36% -35.32% -23.19% -32.97% -2.06% 12.20%
Operating Margin
-109.11% -529.56% -139.93% -105.99% -80.61% -44.66% -21.88% -15.00% -10.12% 9.21%
EBIT Margin
-93.51% -503.67% -141.64% -98.53% -81.63% -45.94% -31.60% -40.37% -9.78% 6.39%
Profit (Net Income) Margin
-93.21% -503.28% -141.38% -95.92% -79.33% -44.89% -32.42% -41.37% -10.81% 5.69%
Tax Burden Percent
99.92% 100.03% 99.76% 99.58% 99.59% 98.43% 99.60% 99.35% 99.44% 100.44%
Interest Burden Percent
99.76% 99.89% 100.06% 97.76% 97.58% 99.27% 103.03% 103.14% 111.22% 88.58%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.44%
Return on Invested Capital (ROIC)
-91.97% -894.27% -163.98% -55.17% -35.70% -30.93% -17.29% -12.49% -9.23% 13.13%
ROIC Less NNEP Spread (ROIC-NNEP)
-87.04% -857.89% -154.38% -48.05% -20.69% -9.25% -2.30% 41.55% 2.61% 29.02%
Return on Net Nonoperating Assets (RNNOA)
51.96% 597.82% 91.61% 15.32% 4.13% 1.39% 0.61% -6.83% -0.28% -2.63%
Return on Equity (ROE)
-40.01% -296.45% -72.36% -39.85% -31.57% -29.54% -16.67% -19.32% -9.50% 10.50%
Cash Return on Invested Capital (CROIC)
0.00% -339.15% -410.30% -47.93% -31.51% -70.26% -59.91% -27.19% -15.06% -9.13%
Operating Return on Assets (OROA)
-30.18% -226.23% -59.67% -33.05% -27.05% -20.46% -14.92% -22.73% -6.33% 4.66%
Return on Assets (ROA)
-30.08% -226.05% -59.56% -32.18% -26.29% -19.99% -15.31% -23.29% -7.00% 4.14%
Return on Common Equity (ROCE)
-40.01% -296.45% -72.36% -39.85% -31.57% -29.54% -16.67% -19.32% -9.50% 10.50%
Return on Equity Simple (ROE_SIMPLE)
-49.96% 0.00% -162.29% -166.85% -180.43% 0.00% -65.16% -60.54% -40.83% 0.00%
Net Operating Profit after Tax (NOPAT)
-64 -227 -42 -36 -30 -18 -9.56 -7.41 -5.45 8.85
NOPAT Margin
-76.38% -370.69% -97.95% -74.19% -56.43% -31.26% -15.32% -10.50% -7.08% 9.25%
Net Nonoperating Expense Percent (NNEP)
-4.93% -36.38% -9.60% -7.12% -15.01% -21.67% -14.99% -54.04% -11.84% -15.89%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - -5.22% - - - 2.47%
Cost of Revenue to Revenue
83.72% 126.61% 64.68% 61.49% 52.61% 46.44% 40.07% 39.09% 37.78% 30.78%
SG&A Expenses to Revenue
66.00% 70.43% 101.27% 76.67% 48.96% 46.37% 35.96% 35.70% 34.01% 28.60%
R&D to Revenue
16.04% 39.72% 33.83% 35.19% 26.81% 21.33% 18.53% 15.46% 15.17% 12.12%
Operating Expenses to Revenue
125.39% 502.94% 175.25% 144.50% 128.00% 98.22% 81.82% 75.92% 72.34% 60.02%
Earnings before Interest and Taxes (EBIT)
-78 -309 -61 -48 -44 -26 -20 -28 -7.52 6.11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-67 -275 -52 -38 -35 -20 -14 -23 -1.59 12
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.60 0.40 0.89 0.52 0.37 0.31 1.14 3.52 5.59 8.61
Price to Tangible Book Value (P/TBV)
1.76 1.52 2.00 1.31 1.20 1.29 6.20 24.04 26.96 24.37
Price to Revenue (P/Rev)
1.45 0.43 1.30 0.65 0.45 0.35 1.07 2.80 4.28 6.91
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.49 0.23 0.80 0.31 0.24 0.27 1.14 3.44 5.68 9.60
Enterprise Value to Revenue (EV/Rev)
0.93 0.19 0.66 0.28 0.24 0.28 1.07 2.83 4.26 6.82
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.13 0.26 0.21 0.24 0.28 0.51 0.55 0.58 0.55 0.46
Long-Term Debt to Equity
0.13 0.26 0.21 0.24 0.28 0.51 0.55 0.58 0.55 0.46
Financial Leverage
-0.60 -0.70 -0.59 -0.32 -0.20 -0.15 -0.27 -0.16 -0.11 -0.09
Leverage Ratio
1.50 1.63 1.62 1.51 1.53 1.89 1.75 1.77 1.80 1.77
Compound Leverage Factor
1.50 1.63 1.62 1.48 1.49 1.87 1.81 1.82 2.00 1.57
Debt to Total Capital
11.51% 20.71% 17.59% 19.12% 21.57% 33.65% 35.55% 36.79% 35.47% 31.51%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
11.51% 20.71% 17.59% 19.12% 21.57% 33.65% 35.55% 36.79% 35.47% 31.51%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
88.49% 79.29% 82.41% 80.88% 78.43% 66.35% 64.45% 63.21% 64.53% 68.49%
Debt to EBITDA
-0.25 -0.12 -0.13 -0.16 -0.17 -0.80 -1.08 -1.23 -1.92 -4.08
Net Debt to EBITDA
0.40 0.11 0.28 0.20 0.11 0.10 -0.01 -0.07 0.07 1.03
Long-Term Debt to EBITDA
-0.25 -0.12 -0.13 -0.16 -0.17 -0.80 -1.08 -1.23 -1.92 -4.08
Debt to NOPAT
-0.23 -0.14 -0.16 -0.19 -0.21 -0.91 -1.22 -1.74 -2.78 -6.94
Net Debt to NOPAT
0.37 0.12 0.32 0.23 0.13 0.11 -0.02 -0.09 0.10 1.74
Long-Term Debt to NOPAT
-0.23 -0.14 -0.16 -0.19 -0.21 -0.91 -1.22 -1.74 -2.78 -6.94
Altman Z-Score
-0.45 -4.38 -1.86 -2.62 -3.48 -3.49 -3.19 -2.08 -0.38 3.95
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.89 1.47 2.29 2.53 2.51 3.10 3.22 2.38 2.41 3.61
Quick Ratio
1.45 1.16 1.98 2.26 2.15 2.77 2.80 1.95 2.00 3.26
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-566 -425 -144 181 203 -35 -34 1.91 4.01 5.45
Operating Cash Flow to CapEx
-2,065.50% -2,278.15% -12,025.97% -1,937.74% 0.00% -1,339.52% -3,704.97% -333.21% -680.34% -104.36%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -4,111.37 0.00 0.00 0.00 -56.33 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 -1,587.43 0.00 0.00 0.00 -27.49 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -1,600.63 0.00 0.00 0.00 -28.23 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.32 0.45 0.42 0.34 0.33 0.45 0.47 0.56 0.65 0.73
Accounts Receivable Turnover
7.05 6.71 6.28 5.85 5.42 5.32 7.10 8.11 7.54 8.67
Inventory Turnover
6.49 11.10 9.91 7.72 6.11 10.03 9.16 9.82 10.76 11.43
Fixed Asset Turnover
3.19 4.11 4.05 3.56 3.44 4.82 5.49 6.53 7.95 9.35
Accounts Payable Turnover
3.67 3.96 3.29 2.37 2.56 1.84 2.06 2.01 2.27 3.29
Days Sales Outstanding (DSO)
51.74 54.36 58.13 62.38 67.41 68.61 51.39 45.01 48.41 42.09
Days Inventory Outstanding (DIO)
56.27 32.89 36.84 47.25 59.72 36.39 39.85 37.18 33.91 31.93
Days Payable Outstanding (DPO)
99.49 92.28 110.79 153.85 142.35 198.35 177.42 181.56 160.60 110.93
Cash Conversion Cycle (CCC)
8.52 -5.03 -15.82 -44.22 -15.23 -93.35 -86.17 -99.37 -78.28 -36.91
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
443 196 185 209 210 213 209 200 200 217
Invested Capital Turnover
1.20 2.41 1.67 0.74 0.63 0.99 1.13 1.19 1.30 1.42
Increase / (Decrease) in Invested Capital
502 198 102 -217 -233 17 24 -9.31 -9.46 3.40
Enterprise Value (EV)
216 44 147 66 49 57 238 689 1,139 2,083
Market Capitalization
334 102 291 153 94 71 236 683 1,143 2,111
Book Value per Share
$1.47 $0.66 $0.41 $11.57 $9.87 $8.81 $7.95 $7.42 $7.59 $8.93
Tangible Book Value per Share
$0.50 $0.17 $0.18 $4.55 $3.03 $2.14 $1.46 $1.09 $1.57 $3.15
Total Capital
634 320 399 366 324 344 322 307 317 358
Total Debt
73 66 70 70 70 116 114 113 112 113
Total Long-Term Debt
73 66 70 70 70 116 114 113 112 113
Net Debt
-118 -58 -144 -87 -44 -15 1.41 6.10 -4.06 -28
Capital Expenditures (CapEx)
4.28 2.84 0.46 2.76 -0.14 2.23 0.44 1.35 0.65 3.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-47 -56 -61 -28 -11 -6.63 -0.22 -13 -7.79 1.97
Debt-free Net Working Capital (DFNWC)
144 68 153 129 103 124 113 94 109 143
Net Working Capital (NWC)
144 68 153 129 103 124 113 94 109 143
Net Nonoperating Expense (NNE)
14 81 19 11 12 7.82 11 22 2.87 3.41
Net Nonoperating Obligations (NNO)
-118 -58 -144 -87 -44 -15 1.41 6.10 -4.06 -28
Total Depreciation and Amortization (D&A)
11 34 8.64 10 8.67 6.09 5.25 5.22 5.93 5.56
Debt-free, Cash-free Net Working Capital to Revenue
-20.37% -23.69% -27.12% -11.74% -5.25% -3.27% -0.10% -5.32% -2.92% 0.64%
Debt-free Net Working Capital to Revenue
62.42% 29.11% 68.48% 54.52% 50.10% 60.98% 50.80% 38.54% 40.66% 46.87%
Net Working Capital to Revenue
62.42% 29.11% 68.48% 54.52% 50.10% 60.98% 50.80% 38.54% 40.66% 46.87%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($6.60) ($995.28) ($3.04) ($1.84) ($1.64) ($1.06) ($0.78) ($1.10) ($0.31) $0.20
Adjusted Weighted Average Basic Shares Outstanding
11.54M 310.21K 20.06M 25.42M 25.79M 24.31M 26.06M 26.62M 27.10M 26.89M
Adjusted Diluted Earnings per Share
($6.60) ($995.28) ($3.04) ($1.84) ($1.64) ($1.06) ($0.78) ($1.10) ($0.31) $0.20
Adjusted Weighted Average Diluted Shares Outstanding
11.54M 310.21K 20.06M 25.42M 25.79M 24.31M 26.06M 26.62M 27.10M 26.89M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($995.28) $0.00 $0.00 $0.00 ($1.06) $0.00 $0.00 $0.00 $0.20
Adjusted Weighted Average Basic & Diluted Shares Outstanding
11.72M 24.19M 25.59M 25.77M 25.88M 26.05M 26.14M 26.94M 27.47M 28.07M
Normalized Net Operating Profit after Tax (NOPAT)
-64 -80 -41 -36 -24 -18 -9.56 -7.41 -5.45 6.16
Normalized NOPAT Margin
-76.38% -130.91% -94.51% -74.19% -45.55% -31.26% -15.32% -10.50% -7.08% 6.45%
Pre Tax Income Margin
-93.29% -503.13% -141.72% -96.32% -79.65% -45.60% -32.55% -41.64% -10.87% 5.66%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 -1,745.74 0.00 0.00 0.00 -33.04 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 -1,207.28 0.00 0.00 0.00 -16.02 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 -1,758.94 0.00 0.00 0.00 -33.78 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 -1,220.48 0.00 0.00 0.00 -16.76 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About GeneDx's Financials

When does GeneDx's fiscal year end?

According to the most recent income statement we have on file, GeneDx's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has GeneDx's net income changed over the last 5 years?

GeneDx's net income appears to be on an upward trend, with a most recent value of -$52.29 million in 2024, rising from -$29.70 million in 2019. The previous period was -$175.77 million in 2023.

What is GeneDx's operating income?
GeneDx's total operating income in 2024 was -$23.21 million, based on the following breakdown:
  • Total Gross Profit: $194.40 million
  • Total Operating Expenses: $217.61 million
How has GeneDx revenue changed over the last 5 years?

Over the last 5 years, GeneDx's total revenue changed from $196.17 million in 2019 to $305.45 million in 2024, a change of 55.7%.

How much debt does GeneDx have?

GeneDx's total liabilities were at $174.13 million at the end of 2024, a 8.7% decrease from 2023, and a 29.6% decrease since 2020.

How much cash does GeneDx have?

In the past 4 years, GeneDx's cash and equivalents has ranged from $85.21 million in 2024 to $400.57 million in 2021, and is currently $85.21 million as of their latest financial filing in 2024.

How has GeneDx's book value per share changed over the last 5 years?

Over the last 5 years, GeneDx's book value per share changed from 0.00 in 2019 to 8.93 in 2024, a change of 892.7%.



This page (NASDAQ:WGSWW) was last updated on 4/21/2025 by MarketBeat.com Staff
From Our Partners